Newsfeeds Archive - Page 8 of 9

1 minute read

Cingulate Q4 EPS $(0.41) Misses $(0.37) Estimate

March 10, 5:05 PM

Cingulate (NASDAQ:CING) reported quarterly losses of $(0.41) per share which missed the analyst consensus estimate of $(0.37) by 10.81 percent. This is a 28.12 percent decrease over losses of $(0.32) per share from the

CING

2 minute read

Tesla, Amazon, Union Pacific, Woodside Energy, Cingulate: Why These 5 Stocks Drawing Investors’ Attention Today

By Bhavik Nair

February 26, 9:14 PM

Major Wall Street indices closed over 1% lower on Friday as the core personal consumption expenditures price index,…

AMZN

3 minute read

Dow Dips 350 Points; S&P 500 Down Over 1%

By Lisa Levin

February 24, 3:35 PM

U.S. stocks traded lower toward the end of trading, with the Dow Jones dropping over 300 points on Friday. The Dow traded down 1.07% to 32,798.91 while the NASDAQ fell 1.90% to 11,370.53. The S&P 500 also fell, dropping, 1.23% to 3,963.05

BAER

1 minute read

Why Cingulate Shares Are Trading Higher Today

By Vandana Singh

February 24, 9:19 AM

Cingulate Inc (NASDAQ:CING) announced positive topline results from the CTx-1301-003 study assessing the effect of food on the absorption of its…

CING

22 minute read

Benzinga’s Top Ratings Upgrades, Downgrades For January 17, 2023

By Benzinga Insights

January 17, 11:01 AM

Upgrades For Casa Systems Inc (NASDAQ:CASA), Northland Capital Markets upgraded the previous rating of Market Perform to Outperform.…

1 minute read

HC Wainwright & Co. Initiates Coverage On Cingulate with Buy Rating, Announces Price Target of $5.5

By Benzinga Newsdesk

January 17, 7:22 AM

HC Wainwright & Co. analyst Raghuram Selvaraju initiates coverage on Cingulate (NASDAQ:CING) with a Buy rating and announces Price Target of $5.5.

CING

1 minute read

Cingulate Kickstarts First Phase 3 Trial For ADHD Candidate, Data Expected In First Half 2023

By Vandana Singh

January 4, 7:45 AM

Cingulate Inc (NASDAQ: CING) has initiated the first Phase 3 clinical trial of its lead candidate CTx-1301, an extended-release tablet formulation of dexmethylphenidate, a compound approved by the FDA for attention-deficit/hyperactivity disorder (ADHD).

CING

1 minute read

Cingulate Files For Mixed-Securities Shelf Offering Of Up To $100M

By Michael Horton

January 3, 6:04 PM

-SEC Filing

CING

5 minute read

Why American Eagle Outfitters Shares Climbed Over 18%; Here Are 78 Biggest Movers From Yesterday

By Lisa Levin

November 23, 6:25 AM

Gainers Cosmos Holdings Inc. (NASDAQ: COSM) jumped 86.9% to close at $0.3275 on Tuesday after jumping 21% on Monday. Cosmos Health agreed to sell its Sky Premium Life Luxury food supplement brand on Iberian Airlines' in-flight magazine, Ronda.

4 minute read

Why Dollar Tree Shares Are Trading Lower By 10%? Here Are 53 Stocks Moving In Tuesday’s Mid-Day Session

By Lisa Levin

November 22, 2:16 PM

Gainers Palisade Bio, Inc. (NASDAQ: PALI) shares jumped 99.1% to $4.42 after the company announced the FDA granted Fast Track designation to LB1148 for the acceleration of time to return of bowel function following surgery.